Corporate Information – Page 37 – Alligator Bioscience

2017-11-21

Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017

Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceu ...

2017-11-13

Lund, Sweden, 13 November, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...

2017-11-07

Regulatory

Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...

2017-10-24

Regulatory

ALG.APV-527 – A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Eng ...

2017-09-21

Regulatory

Lund, Sweden, September 21, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...

2017-09-13

Regulatory

Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...

2017-08-17

Regulatory

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications Seattle, WA, and Lund, Sweden – August ...

2017-08-07

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing tumor-directed immunotherapies for canc ...

2017-07-21

Regulatory

Strategic partnership will advance development of a novel bispecific immuno-oncology antibody targeting compelling biological pathway implic ...